«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2023年01期

页码:

64-66

栏目:

临床研究

出版日期:

2023-02-20

文章信息/Info

Title:

-

作者:

孙 龙¹; 政红卫¹; 俞玲玲¹; 甄 杰²

226200 江苏,南通大学附属启东医院/启东市人民医院病理科¹、胸外科²

Author(s):

-

关键词:

非小细胞肺癌;  成纤维细胞生长因子受体3;  G1/S特异性周期蛋白D1;  预后分析

Keywords:

-

分类号:

R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2023.01.015

摘要:

目的 分析非小细胞肺癌(non-small cell lung cancer, NSCLC)成纤维细胞生长因子受体3(fibroblast growth factor receptor 3, FGFR3)、G1/S特异性周期蛋白D1(CyclinD1)表达与临床病理特征及预后关系。 方法 选取2018年1月1日至2020年12月31日我院收治的NSCLC患者80例为对象。免疫组织化学检测NSCLC肿瘤组织中的FGFR3及CyclinD1; 采用构建突变引物并PCR扩增检测组织中FGFR3突变; 分析FGFR3表达、突变及CyclinD1表达与NSCLC关系。 结果 FGFR3高表达易出临床分期、淋巴结转移及EGFR突变阴性(P<0.05),FGFR3突变易出现中低分化、临床分期、淋巴结转移及EGFR突变阴性(P<0.05),CyclinD1高表达易出现中低分化、淋巴结转移及EGFR突变阳性(P<0.05); CyclinD1高表达易出现FGFR3^+/MUT的活化形式(P<0.05); NSCLC临床分期、淋巴结转移、EGFR状态、FGFR3高表达、FGFR3突变及CyclinD1高表达为患者出现预后(P<0.05); FGFR^3+/MUT患者的PFS及OS差于FGFR^3-/MUT患者(P<0.05)。 结论 FGFR3在NSCLC中存在异常活化,包括突变及过表达,两种方式同时激活通过CyclinD1促进肿瘤发展具有意义。

Abstract:

-

参考文献/References:

1 徐 瑜, 白 莉. 广泛期小细胞肺癌免疫治疗新理念[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 407-411.
2 王洪武, 金发光. 晚期非小细胞肺癌多域整合治疗策略[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(4): 457-461.
3 Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives [J]. Crit Rev Oncol Hematol, 2021, 157: 103194.
4 Chew NJ, Nguyen EV, Su SP, et al. FGFR3 signaling and function in triple negative breast cancer [J]. Cell Commun Signal, 2020, 18(1): 13.
5 钟 键, 金正贤, 卞卫星, 等. 膀胱癌组织FGFR3基因突变和蛋白表达与预后关系研究 [J]. 中华肿瘤防治杂志, 2020, 27(2): 130-135.
6 邓 敏, 解瑞飞, 王 惠. FGFR-1、cyclinD1在乳腺癌中的表达及其临床意义 [J]. 中国现代医生, 2016, 54(4): 1-4.
7 Yanan Liu, Meng Cao, Yuepiao Cai, et al. Dissecting the role of the FGF19-FGFR4 signaling pathway in cancer development and progression[J]. Front Cell Dev Biol, 2020, 8: 95.
8 Yuanyuan Shi, Xuejiao Liu, Mangaladoss Fredimoses, et al. FGFR2 regulation by picrasidine Q inhibits the cell growth and induces apoptosis in esophageal squamous cell carcinoma[J]. J Cell Biochem, 2018, 119(2): 2231-2239.
9 Ramón Rami-Porta, Wilfried EE Eberhardt. Clinical implications of the innovations in the primary tumour and metastasis of the 8(th)edition of the TNM classification for lung cancer[J]. J Thorac Dis, 2018, 10(Suppl 22): S2682-S2685.
10 Yijun Wang, Danfei Liu, Tongyue Zhang, et al. FGF/FGFR signaling in hepatocellular carcinoma: from carcinogenesis to recent therapeutic intervention[J]. Cancers, 2021, 13(6): 1360.
11 Liu G, Chen T, Ding Z, et al. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment [J]. Cell Prolif, 2021, 54(4): e13009.
12 Mariangela Tamburello, Barbara Altieri, Iuliu Sbiera, et al. FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma[J]. Endocrine, 2022, 77(3): 411-418.
13 Maria Francesca Santolla, Marcello Maggiolini. The FGF/FGFR system in breast cancer: Oncogenic features and therapeutic perspectives[J]. Cancers(Basel), 2020, 12(10): 3029.
14 Jakub Szymczyk, Katarzyna Dominika Sluzalska, Izabela Materla, et al. FGF/FGFR-dependent molecular mechanisms underlying anti-cancer drug resistance[J]. Cancers(Basel), 2021, 13(22): 5796.
15 Yangli Xie, Nan Su, Jing Yang, et al. FGF/FGFR signaling in health and disease[J]. Signal Transduct Target Ther, 2020, 5(1): 181.
16 陈 印, 顾 鹏, 李秋艳, 等. FGFR3在膀胱癌发生及靶向治疗中作用的研究进展 [J]. 山东医药, 2018, 58(37): 94-97.
17 Jing W, Wwang G, Cui Z, et al. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance[J]. Cancer Research, 2022, 82(1): 114-129.
18 Zhao J, Tan W, Zhang L, et al. FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer[J]. Biochem Pharmacol, 2021,190: 114536.
19 Cappellen D, C De Oliveira, D Ricol, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas [J]. Nat Genet, 1999, 23(1): 18-20.
20 Bas W G van Rhijn, Laura S Mertens, Roman Mayr, et al. FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: Implications for anti-FGFR3 treatment? [J]. Eur Urol, 2020, 78(5): 682-687.
21 Junling Fu, Yiting Zhao, Tong Wang, et al. Acanthosis nigricans in a Chinese girl with FGFR3 K650 T mutation: a case report and literature review[J]. BMC Med Genet, 2019, 20(1): 8.
22 Nan Li, Sheng Mou Lin, Yingting Li, et al. An induced pluripotent stem cell line(GZHMCi004-A)derived from a fetus with heterozygous G380R mutation in FGFR3 gene causing achondroplasia[J]. Stem Cell Res, 2021, 53: 102322.
23 Gust KM, McConkey DJ, Awrey S, et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer[J]. Mol Cancer Ther, 2013, 12(7): 1245-1254.
24 Edyta Marta Borkowska, Magdalena Traczyk-Borszynska, Piotr Kutwin,et al. Usefulness of droplet digital PCR and Sanger sequencing for detection of FGFR3 mutation in bladder cancer [J]. Urol Oncol, 2019, 37(12): 907-915.
25 Liu J, Tao LL, Yu GY, et al. Diagnostic significance of CyclinD1 and D2-40 expression for follicular neoplasm of the thyroid[J]. Pathology, Research, Practice, 2022, 229: 153739.
26 Qi Y, Wang D, Huang W, et al. CyclinD1 inhibits dicer and crucial miRNA expression by chromatin modification to promote the progression of intrahepatic cholangiocarcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 413.
27 Roland Seiler, George N Thalmann, Diana Rotzer, et al. CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response [J]. Mod Pathol, 2014, 27(1): 87-95.

备注/Memo

备注/Memo:

通信作者: 甄 杰, Email: 1343915346@qq.com

常用功能

更新日期/Last Update: 2023-02-20